PNPLA3 and hepatocellular carcinoma: The association for liver disease protection among statin users was evident for HCC among carriers heterozygous for the PNPLA3 rs738409 risk allele (HR, 0.31; 95% CI, 0.11-0.85; P = .02) (eTable 6 in Supplement 1).